The DOI matches its Crossref record; 128 of the 131 references it cites were found in a registry or an index, and 3 are not checked yet.
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor–Resistant Disease
Open accessAbstract
Purpose: EGFR-mutant lung cancer was first described as a new clinical entity in 2004. Here, we present an update on new controversies and conclusions regarding the disease. Methods: This article reviews the clinical implications of EGFR mutations in lung cancer with a focus on epidermal growth factor receptor tyrosine kinase inhibitor resistance. Results: The discovery of EGFR mutations has altered the ways in which we consider and treat non–small-cell lung cancer (NSCLC). Patients whose metastatic tumors harbor EGFR mutations are expected to live longer than 2 years, more than double the previous survival rates for lung cancer. Conclusion: The information presented in this review can guide practitioners and help them inform their patients about EGFR mutations and their impact on the treatment of NSCLC. Efforts should now concentrate on making EGFR-mutant lung cancer a chronic rather than fatal disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Despite initial efficacy, resistance to TKIs invariably develops, with disease progression after an average of approximately 12 months6.”
From RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer (2015) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Flagged first, then by citations
Research works printed but not linked: 1
- Woodcock J, 2012, Federal Register, 77, 24723
Cited by
Sorted by citations
Items 401–480 of 480
Nakasuka, T., Ohashi, K., Nishii, K., Hirabae, A., Okawa, S., Tomonobu, N., Takada, K., Ando, C., Watanabe, H., Makimoto, G., et al. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.01.018 · Cited by 1
Self-citationLiu, Q., Tan, L., He, J., Ning, R., Zeng, A., & Chen, Y. (2023) · International Journal of General Medicine · doi:10.2147/ijgm.s437495 · Cited by 1
Kim, M., & Kim, M. H. (2025) · Oncology Reports · doi:10.3892/or.2025.8946 · Cited by 1
Ahmed, R. A., Muralidharan, R., Amreddy, N., Srivastava, A., Mehta, M., Panneerselvam, J., de Castro, R. O., Berry, W. L., Ghosh, S., Murali, R., et al. (2025) · Cancers · doi:10.3390/cancers18010062 · Cited by 1
[Effect and Significance of BIM on Non-small Cell Lung Cancer].
Wang, J., & Xin, T. (2016) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2016.11.12 · Cited by 1
Song, J., Zang, Y., Li, W., Zhong, W., Shi, J., Dong, D., Fang, M., Liu, Z., & Tian, J. (2017) · Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE · doi:10.1117/12.2253998 · Cited by 1
Hiura, T., Saida, Y., Koyama, K., Abe, T., Tanaka, H., & Yokoyama, A. (2015) · Haigan · doi:10.2482/haigan.55.155 · Cited by 1
Mori, M., Sawa, N., Hosono, Y., Kanazu, M., Akazawa, Y., & Yano, Y. (2017) · Haigan · doi:10.2482/haigan.57.211 · Cited by 1
Matsumoto, C., Tamura, T., Kawajiri, T., Nishi, T., Kudo, K., & Kuyama, S. (2019) · Haigan · doi:10.2482/haigan.59.151 · Cited by 1
Bourdeanu, L., Liu, E. Y., Brint, S., & Langdon, D. E. (2017) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-70142-4_4 · Cited by 1
Kasuma, D., Soeroso, N. N., Tarigan, S. P., & Syahruddin, E. (2022) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2022.9459 · Cited by 1
He, D., Yuan, R., & Liu, L. (2023) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-023-10520-7 · Cited by 1
PROTACs in the Management of Prostate Cancer
Mandlik, D. S., & Mandlik, S. K. (2024) · Springer eBooks · doi:10.1007/978-981-97-5077-1_11 · Cited by 1
Yamamoto, A., Isobe, K., Kaburaki, K., Kinoshita, A., Wada, T., Sano, G., Sakamoto, S., Takai, Y., Shibuya, K., & Homma, S. A. (2014) · Haigan · doi:10.2482/haigan.54.1 · Cited by 1
Pharmacogenomics in Lung Cancer
Simon, G. R., Rosell, R., & Gandara, D. R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-52357-8.00047-0 · Cited by 1
Kubo, N., Harada, T., Shiraishi, Y., Nosaki, K., Nakagaki, N., Takeshita, M., Ouchi, H., Iwama, E., Tanaka, K., Okamoto, I., et al. (2019) · Anticancer Research · doi:10.21873/anticanres.13162 · Cited by 1
[Advanced Research on Non-small Cell Lung Cancer with De Novo T790M Mutation].
Wang, X., & Zhong, D. (2019) · PubMed Central · doi:10.3779/j.issn.1009-3419.2019.05.10 · Cited by 1
[Disparities of EGFR mutations between Biopsy and Rebiopsy in Non-small Cell Lung Cancer Patients].
Li, H., Yan, S., Liu, X., Liu, Y., Ma, L., Wang, Y., Liu, Y., & Cheng, Y. (2018) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2018.11.03 · Cited by 1
Case Study on Receptor Tyrosine Kinases EGFR, VEGFR, and PDGFR
Lima, L. M., Barbosa, M. L. D. C., do Amaral, D. N., & Barreiro, E. J. (2020) · Topics in medicinal chemistry · doi:10.1007/7355_2020_95 · Cited by 1
Herreros‐Pomares, A. (2020) · RiuNet (Universitat Politècnica de València) · doi:10.4995/thesis/10251/137036 · Cited by 1
Predictive biomarkers in diffuse gliomas and non-small cell lung cancer
Merkkiniemi, K. (2015) · Työväentutkimus Vuosikirja
Strategy on Patients with EGFR Mutation
Früh, M., Zhou, Q. H., Leung, L. K. S., & Mok, T. S. K. (2014) · Springer eBooks · doi:10.1007/978-3-319-06062-0_9
Utility of Next-Generation Sequencing in Cancer Drug Development and Clinical Trials
Thomas, F., & Awada, A. H. (2015) · Springer eBooks · doi:10.1007/978-3-319-15811-2_2
Aspects biologiques des cancers bronchiques
Mascaux, C. (2014) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(14)70584-1
Bar, J., Damianovich, M., Hout‐Siloni, G., Dar, E., Cohen, Y., Zadok, O., Cohen, Y., Perelman, M., Barshack, I., Yarden, R. I., et al. (2014) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-014-0132-1
Thérapies ciblées : comment déterminer la cible ?
Remmelink, M. (2014) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(14)70600-7
Cho, N. J., Lee, H.-S., Jang, S., Choi, J. S., Na, J. O., Seo, K. H., Kim, Y. H., Kang, H.-C., & Kim, D.-Y. (2013) · Soonchunhyang Medical Science · doi:10.15746/sms.13.028
Pujol, J.-L., Vignot, S., di Mercurio, J.-P., & Quantin, X. (2013) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(13)70454-3
New Treatment Strategy for Patients with EGFR -Mutant Lung Cancer
Ninomiya, T., Takigawa, N., Toyooka, S., Hotta, K., Tanimoto, M., & Kiura, K. (2013) · Lung Cancer Management · doi:10.2217/lmt.13.63
Chemotherapy: Still an Essential Player in Non-Small-Cell Lung Cancer Treatment?
Ferreira, C. G., Montella, T. C., Baldotto, C. S. D. R., & Domingues, P. M. (2013) · Lung Cancer Management · doi:10.2217/lmt.13.43
Genetic and Epigenetic Determinants of Lung Cancer Subtype: Adenocarcinoma to Small Cell Conversion
Rudin, C. M. (2015) · Defense Technical Information Center (DTIC) · doi:10.21236/ada623599
Cancers bronchiques non à petites cellules mutés ou réarrangés : de la premiere á la énième ligne
Raimbourg, J., & Douillard, J. (2015) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(16)30032-5
Targeted Therapy in Solid Tumors: Lung Cancer
Waqar, S. N., Morgensztern, D., & Herbst, R. S. (2015) · doi:10.1002/9781118468678.ch23
Non-small cell lung cancer and superior vena cava obstruction
Beaton, L., Wong, S., & Mulatero, C. (2015) · doi:10.1093/med/9780199688883.003.0002
Reichegger, H., Jochum, W., Förbs, D., Hader, C., & Früh, M. (2017) · Kompass Pneumologie · doi:10.1159/000455111
Gao, Y. (2017) · Biomedical Research-tokyo
EGFR EXPRESSION IN RECTAL CANCER, RELATION TO THE FREAQUENCY OF LYMPH NODE METASTASIS
Stepanov, I. V., Рафаэльевич, А. С., Krakhmal, N. V., Владимирович, Р. К., Sorokin, D. A., Afanasyev, S. G., Vtorushin, S. V., & Zavyalova, M. V. (2017) · Siberian Journal of Oncology · doi:10.21294/1814-4861-2017-16-2-42-49
Zhang, C., Hou, H., Cheng, X., Gong, D.-X., Ling, Y., Liu, H., Zhu, W., Zhou, N., Zhu, Y., Chen, L., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23720
Güven, E. S., & Gülhan, S. Ş. E. (2018) · Current Thoracic Surgery · doi:10.26663/cts.2018.00019
Petersen, I., Fisseler-Eckhoff, A., Warth, A., & Weichert, W. (2014) · Der Onkologe · doi:10.1007/s00761-014-2677-3
Wang, C., Lai, C., Chang, H., Tseng, C., Huang, K., & Lin, M. (2021) · Research Square · doi:10.21203/rs.3.rs-554803/v1
Xie, X., Li, L., Xie, L., Liu, Z., Gao, X., Xia, X., Deng, H., Yang, Y., Yang, M., Chang, L., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3970228
Yin, L., Zhan, J., Liao, H., Qiu, W., Hou, W., Li, S., & Zhang, J. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174907
LIX1L promotes EMT and EGFR-TKIs resistance via nucleolin-mediated ribosomal RNA synthesis in NSCLCPreprint
Li, M., Zhang, J., Meng, X., Liu, B., Xie, S. M., Liu, F., Yao, D., Zhang, J., Shen, H., & Lingxiao, X. (2022) · Research Square · doi:10.21203/rs.3.rs-1749938/v1
Zhou, F., & Ding, K. (2022) · Wiley eBooks · doi:10.1002/9781119847281.ch9
Schulz, W. A. (2023) · Springer eBooks · doi:10.1007/978-3-031-16286-2_23
Data from InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma
Ma, Y., Tang, N., Thompson, R. C., Mobley, B. C., Clark, S. W., Sarkaria, J. N., & Wang, J. (2023) · doi:10.1158/1078-0432.c.6524027.v1
Schulz, W. A. (2024) · Springer eBooks · doi:10.1007/978-3-031-42806-7_23
Huang, Y., Qin, S., Tang, H., Jiang, J., & Liang, Q. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114368
Zhao, G., Zhao, G., Li, M., & Wang, X. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5228993
Kungyal, T., & Tsamchoe, M. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.26.659534
Lei, Y., Lv, G., Yang, Q., Duan, J., & Shi, Y. (2025) · Journal of Visualized Experiments · doi:10.3791/68770
Watcharenwong, P., Trachu, N., Iemwimangsa, N., Munthum, D., Monnamo, N., Jiaranai, P., Charoenyingwattana, A., Nitiwarangkul, C., Chamroonrat, W., Chansriwong, P., et al. (2026) · BMC Cancer · doi:10.21203/rs.3.rs-7683102/v1
Pan, K., Xu, B., Lou, Y. L. G., Xue, J., Jin, X., Dang, M., Pan, S.-Y., Huang, Z., & Chen, X. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117562
Shi, J., Wang, Y., Pang, J., Yin, J. C., He, C., Zhang, Z., & Xie, H. (2025) · BMC Cancer · doi:10.1186/s12885-025-14885-4
Molecular mechanisms of drug-tolerance to EGFR-targeted therapies in lung adenocarcinoma
Léonce, C. (2021) · theses.fr (ABES) · doi:10.70675/0611e924z7044z428cz90dcz9235e0a4b5a2
Li, Z., Lou, Y., Wei, Y., Guan, J., Xu, M., Chen, B., & Ou, W. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.152219
Nishimura, J., Kuribayashi, T., Braegelmann, J., Okawa, S., Taoka, M., Mori, S., Nishimura, T., Tanaka, T., Makimoto, G., Ninomiya, K., et al. (2026) · Molecular Oncology · doi:10.1002/1878-0261.70264
Self-citationTanaka, T., Fujitani, M., Taoka, M., Shimomura, I., Okawa, S., Mori, S., Kuribayashi, T., Nishimura, J., Nishimura, T., Morita, A., et al. (2026) · Cancer Science · doi:10.1111/cas.70431
Self-citationMalangwa, G., Mushengezi, B., Lyatuu, L., Mwapule, L., Mosha, I., Hondo, A., Mashaka, A., Nyanza, B., Mgomi, M., Kessy, A., et al. (2026) · Journal of Medical Case Reports · doi:10.1186/s13256-026-06232-3
Lee, J.-Y., Chung, C., Tseng, T.-T., Kuo, S.-H., Liu, Y.-P., Wu, M.-T., Tsai, H., & Kwan, A. (2026) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-026-06544-3
Wang, B., Donati, V., Gregori, A., Leonetti, A., Pastore, A., Deng, D., & Giovannetti, E. (2026) · iScience · doi:10.1016/j.isci.2026.116999
BindingDB (2020) · UC San Diego · doi:10.7270/q25x2cjz
BindingDB Entry 50047333: Recent progress on third generation covalent EGFR inhibitors.
BindingDB (2017) · UC San Diego · doi:10.7270/q2c24z9v
BindingDB (2020) · UC San Diego · doi:10.7270/q2hh6nmn
BindingDB (2017) · UC San Diego · doi:10.7270/q2ks6tdd
BindingDB Entry 50014757: Discovery and optimization of covalent EGFR T790M/L858R mutant inhibitors.
BindingDB (2023) · UC San Diego · doi:10.7270/q2g164p6
Ichihara, E., Hotta, K., & Kiura, K. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000583
Metadata
- Authors
- Ohashi, K., Maruvka, Y. E., Michor, F., & Pao, W.
- Affiliations
- Harvard University (US)
- Kadoaki Ohashi and William Pao, Vanderbilt University School of Medicine, Nashville, TN; and Yosef E. Maruvka and Franziska Michor, Dana-Farber Cancer Institute and Harvard School of Public Health, Boston, MA.
- Venue
- Journal of Clinical Oncology
- Published
- 2013-03-10
- Volume
- 31
- Issue
- 8
- Pages
- 1070-1080
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- PMC
- PMC3589701
- OpenAlex
- W2081801534
- Cited by
- 467
- References
- 128
- Citations by year
- 2026: 9 · 2025: 15 · 2024: 13 · 2023: 19 · 2022: 28 · 2021: 23 · 2020: 31 · 2019: 34 · 2018: 42 · 2017: 58 · 2016: 44 · 2015: 66 · 2014: 54 · 2013: 30
- FWCI
- 10.14
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Oncology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (CA68485, CA129243, CA143798)
- National Cancer Institute (P30 CA 68485, R01CA121210, P01CA129243, CA68485, CA129243, U54CA143798, CA143798, P30CA068485)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- EGFR mutation, non-small cell lung cancer, EGFR tyrosine kinase inhibitors, drug resistance, metastatic lung cancer, survival outcomes, targeted therapy
- MeSH terms
- Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Chronic Disease, Humans, Lung Neoplasms, Mutation, Disease Progression, Disease-Free Survival, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
